Join to View Full Profile
1515 Holcombe BoulevardUnit Number: 426Houston, TX 77030
Phone+1 713-792-2828
Fax+1 713-563-0541
Dr. Kaseb is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Editor-in-Chief, J of HCC. Director, HCC Program
Education & Training
Henry Ford Health/Henry Ford HospitalFellowship, Hematology and Medical Oncology, 2005 - 2007
Wayne State University School of MedicineResidency, Internal Medicine, 2001 - 2004
Cairo University School of MedicineClass of 1998
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2022 - 2027
TN State Medical License 2022 - 2027
GA State Medical License 2022 - 2026
LA State Medical License 2022 - 2026
TX State Medical License 2007 - 2026
WA State Medical License 2022 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery Start of enrollment: 2005 Oct 01
- Taxoprexin® Treatment for Advanced Primary Cancers of the Liver Start of enrollment: 2007 Jan 01
- Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery Start of enrollment: 2007 May 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsSoftware-based versus visual assessment of the minimal ablative margin in patients with liver tumours undergoing percutaneous thermal ablation (COVER-ALL): a randomise...Bruno C Odisio, Jessica Albuquerque, Yuan-Mao Lin, Brian M Anderson, Caleb S O'Connor
The Lancet. Gastroenterology & Hepatology. 2025-05-01 - Local Control and Extended Survival in Locally Advanced Hepatocellular Carcinoma.Alexander D Sherry, Ahmed O Kaseb, Ethan B Ludmir
JAMA Oncology. 2025-04-10 - Erratum to 'Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial' [Cli...Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong
Clinical and Molecular Hepatology. 2025-04-01
Journal Articles
- Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational StudyFelipe Samaniego, Boris Blechacz, Ahmed Kaseb, Bruno P Granwehr, Aung Naing, Issam I Raad, Ethan Miller, Harrys A Torres, Nature
Lectures
- Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
What’s New in Treating Hepatocellular Carcinoma, the Most Common Liver Cancer?April 14th, 2023- Perioperative Opdivo Alone, in Combination with Yervoy Safe in Patients with HCCMarch 18th, 2022
- MD Anderson Research Highlights for March 9, 2022March 9th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
